$NVCR

Ocean Allyson J sold $46K of NVCR

Ocean Allyson J sold 2,945 shares of NovoCure Ltd (NVCR) at $15.77 on 2026-06-02.

Original reporting
SEC EDGAR · Ocean Allyson J
Published Jun 3, 2026, 8:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NVCR
Neutral
medium confidence
Mentioned
$NVCR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVCRNeutralLow
01

Why it matters

This provides a datapoint on director-level selling but does not include any operational or clinical update.

02

Market read

Traders may briefly reassess sentiment around NVCR, but the disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing does not state reasons for sale; also, Form 4 timing can lag actual trades and may not reflect new information.

Relevance 5/10Novelty 3/10Timing: after-hours/next-session read-through from a just-filed Form 4

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for NovoCure, filed the same day as the sale date.

Company-level read

Ticker impact

$NVCRNeutralMedium confidence
Context

NovoCure director Ocean Allyson J sold 2,945 shares in an open-market transaction for about $46.4K, disclosed via SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief unless followed by additional disclosures or fundamental catalysts.

Evidence & confidence

The filing is an ownership-change disclosure with a small dollar amount and no stated linkage to earnings, trials, or guidance.

Market effects

Limited read-across to biotech/oncology peers; insider Form 4s are common and typically low signal absent pattern or material size.

None.

None.

Counterpoint

A non-10b5-1 sale can be routine liquidity/portfolio rebalancing; the small size suggests no major conviction shift.

Key entities

  • NovoCure Ltd

    Company whose director sold shares; subject of the SEC Form 4 disclosure.

  • Ocean Allyson J

    Director who executed an open-market sale of 2,945 NVCR shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.

$NVCRHighAI 9/10

Novocure’s Optune Pax approved in Japan for unresectable locally advanced pancreatic cancer

Novocure received approval from Japan's MHLW for Optune Pax to treat unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel. The approval follows Phase 3 PANOVA-3 trial results showing improved median overall survival and delayed pain progression. The safety profile included expected skin events. According to the company, no new systemic safety signals were observed.

$NVCRHighAI 9/10

NovoCure Ltd (NVCR): Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

NovoCure Ltd (NVCR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer Baar, Switzerland – October 1, 2026 – Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Op